NCT04773665View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

November 14, 2022

Study Completion Date

November 14, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

VBI-2902a

VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.

BIOLOGICAL

Placebo

0.9% sodium chloride

BIOLOGICAL

VBI-2905a

VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.

Trial Locations (4)

Unknown

Canadian Center for Vaccinology, Halifax

Manna Toronto, Toronto

K1H 8L6

Ottawa Hospital, Ottawa

M4G 3E8

LMC Manna - Bayview CPU, Toronto

All Listed Sponsors
lead

VBI Vaccines Inc.

INDUSTRY

NCT04773665 - Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a | Biotech Hunter | Biotech Hunter